Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23707618 | 0.82 | GABRR1 (0.30) | — | |
| SCHEMBL13246021 | 0.82 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL28915150 | 0.80 | TSHR (0.39) | TSHRTDP1 | |
| SCHEMBL598372 | 0.80 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL4167824 | 0.80 | CYP2D6 (0.50) | ALDH1A1CYP2D6GABBR2GABBR1 | |
| SCHEMBL8007439 | 0.79 | ALDH1A1 (0.30) | ALDH1A1CYP2D6GABBR2GABBR1 | |
| SCHEMBL21472090 | 0.78 | ALDH1A1 (0.33) | ALDH1A1CYP2D6GABBR2GABBR1 | |
| SCHEMBL13060093 | 0.77 | — | — | |
| SCHEMBL19227358 | 0.77 | — | — | |
| SCHEMBL9845113 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163165-A1 | LOW MOLECULAR WEIGHT PRODUCTS AND USE THEREOF AS REVERSIBLE OR PERMANENT LOW-TEMPERATURE CROSSLINKING AGENT IN DIELS-ALDER REACTIONS | EVONIK DEGUSSA GMBH (DE) | 2014-06-12 | — | — | US | claimed |
| US-7557242-B2 | Multistage continuous preparation of cycloaliphatic disocyanates | DEGUSSA AG (DE) | 2009-07-07 | — | — | US | claimed |
| US-7420080-B2 | Multistage continuous preparation of cycloaliphatic diisocyanates | DEGUSSA AG (DE) | 2008-09-02 | — | — | US | claimed |
| US-20050250960-A1 | Phosgene-free; reacting a cycloaliphatic diamine with a carbonic acid derivative and an alcohol to produce a cycloaliphatic diurethane, distillation, thermally cleaving the cycloaliphatic diurethane to produce a cycloaliphatic diisocyanate, recycling reurethanization product directly into the low-boiler | DEGUSSA AG (DE) | 2005-11-10 | — | — | US | claimed |
| EP-3206244-A1 | NEGATIVE ELECTRODE ACTIVE SUBSTANCE FOR NONAQUEOUS ELECTROLYTE SECONDARY CELL, NEGATIVE ELECTRODE FOR NONAQUEOUS ELECTROLYTE SECONDARY CELL, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND METHOD FOR PRODUCING NEGATIVE ELECTRODE MATERIAL FOR NONAQUEOUS ELECTROLYTE SECONDARY CELL | Shin-Etsu Chemical Co., Ltd. (JP) | 2017-08-16 | — | — | EP | disclosed |
| US-20140163165-A1 | LOW MOLECULAR WEIGHT PRODUCTS AND USE THEREOF AS REVERSIBLE OR PERMANENT LOW-TEMPERATURE CROSSLINKING AGENT IN DIELS-ALDER REACTIONS | EVONIK DEGUSSA GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| EP-2500349-A1 | Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections | Universitätsklinikum Freiburg (DE) | 2012-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163165-A1 | LOW MOLECULAR WEIGHT PRODUCTS AND USE THEREOF AS REVERSIBLE OR PERMANENT LOW-TEMPERATURE CROSSLINKING AGENT IN DIELS-ALDER REACTIONS | DCLRE1A, ACP1, DERA | ALDH1A1 190/4885CYP2D6 4462/4885GABBR2 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.